Alan Arrieira Azambuja
Pontifícia Universidade Católica do Rio Grande do Sul
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Alan Arrieira Azambuja.
Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2011
Marcia Angelica Peter Maahs; Alan Arrieira Azambuja; Maria M. Campos; Fernanda Gonçalves Salum; Karen Cherubini
This work aimed at determining whether bisphosphonate therapy produces a sufficient condition for jaw osteonecrosis after tooth extraction.
Hepatology Research | 2003
Claudia Alessandra Fortes Aiub; Roberta G. Bortolini; Alan Arrieira Azambuja; José Carlos Farias Alves Filho; Fernanda Bordignon Nunes; Jarbas Rodrigues de Oliveira
Galactosamine (GalN) is a hepatotoxic agent, which under determined situations provokes metabolic and energetic depletion as well as alterations in permeability, leading to cellular death. At the same time, it is known that fructose-1,6-bisphosphate (FBP) helps maintain cell energy levels and protects the cell against this lesive agent. We submitted two groups of male Wistar rats to the harmful intraperitoneal doses of GalN (400 mg/kg), one of which simultaneously received FBP (2 g/kg). Techniques were used in the analysis of the cellular components, adenosine triphosphate (ATP) and hepatic calcium and a close relationship between the types of cellular death unchained by these agents was established. The liver of the rats treated with GalN showed energy depletion and concomitant increase calcium in the hepatic tissue, which provoked higher levels of necrosis leading to reduce cellular viability. On the other hand, the group which had received GalN+FBP maintained calcium levels close to the control values and the energy rate did not decrease as much as in the GalN only group, but recovered the control values, within a period of 48 h. At the same time, the degree of apoptosis was greater than in the GalN group. This fact suggests that the FBP maintains cellular levels of ATP, thus protecting the cell from the toxic action of GalN, reducing the percentage of dead cells and causing an alteration in the pattern of the cell death, whereby there is an increase in the rate of apoptosis and a decrease in that of necrosis.
Journal of Oral Pathology & Medicine | 2012
Ana Carolina Vasconcelos; Soraya de Azambuja Berti-Couto; Alan Arrieira Azambuja; Fernanda Gonçalves Salum; Maria Antonia Zancanaro de Figueiredo; Vinicius Duval da Silva; Karen Cherubini
BACKGROUND The aim of this study was to compare clodronate and zoledronic acid regarding their influence on the repair of surgical wounds in maxillae (soft tissue wound and tooth extraction) and their relation to osteonecrosis. MATERIAL AND METHODS Thirty-four Wistar rats were allocated into three groups according to the treatment received: (i) 12 animals treated with zoledronic acid, (ii) 12 animals treated with clodronate and (iii) 10 animals that were given saline solution. All animals were subjected to tooth extractions and surgically induced soft tissue injury. Histological analysis of the wound sites was performed by means of hematoxylin-eosin (H&E) staining and immunohistochemical staining for receptor activator of nuclear factor-kB ligand (RANKL), osteoprotegerin (OPG), von Willebrand factor, and caspase-3. RESULTS The zoledronic acid group showed higher incidence of non-vital bone than did the clodronate group at the tooth extraction site. At the soft tissue wound site, there were no significant differences in non-vital bone between the test groups. RANKL, OPG, von Willebrand factor, and caspase-3 did not show significant differences between the groups for both sites of surgical procedures. CONCLUSION Both of the bisphosphonates zoledronic acid and clodronate are capable of inducing maxillary osteonecrosis. Immunohistochemical analysis suggests that the involvement of soft tissues as the initiator of osteonecrosis development is less probable than has been pointed out.
Urologic Oncology-seminars and Original Investigations | 2010
Joseli Stella; Luci Bavaresco; Elizandra Braganhol; Liliana Rockenbach; Patrícia Fernandes Farias; Márcia R. Wink; Alan Arrieira Azambuja; Carlos H. Barrios; Fernanda Bueno Morrone; Ana Maria Oliveira Battastini
Inflammation | 2011
Alan Arrieira Azambuja; Adroaldo Lunardelli; Fernanda Bordignon Nunes; Patrick Gaspareto; Márcio Vinícius Fagundes Donadio; Carlos Eduardo Poli de Figueiredo; Jarbas Rodrigues de Oliveira
Applied Cancer Research | 2009
Fernanda Bueno Morrone; Fernando Spiller; Maria Isabel Albano Edelweiss; Louise Meurer; Paula Engroff; Carlos H. Barrios; Alan Arrieira Azambuja; Diogo Losch de Oliveira; Guido Lenz; Ana Maria Oliveira Battastini
Clinical Oral Investigations | 2017
Miguel Luciano Silva; Leandro Tasso; Alan Arrieira Azambuja; Maria Antonia Zancanaro de Figueiredo; Fernanda Gonçalves Salum; Vinicius Duval da Silva; Karen Cherubini
Revista Odonto Ciência | 2009
Marcia Angelica Peter Maahs; Vanessa Paim Nora; Alan Arrieira Azambuja; Karen Cherubini
Rev. bras. anal. clin | 2004
Rômulo Martins Kaiser; Alan Arrieira Azambuja; Adroaldo Lunardelli; Jarbas Rodrigues de Oliveira
VITTALLE - Revista de Ciências da Saúde | 2016
Paula Engroff; Vanessa Sgnaolin; Alan Arrieira Azambuja; Fabiana Viola; Ana Maria Oliveira Battastini; Fernanda Bueno Morrone
Collaboration
Dive into the Alan Arrieira Azambuja's collaboration.
Maria Antonia Zancanaro de Figueiredo
Pontifícia Universidade Católica do Rio Grande do Sul
View shared research outputs